The Oviduct And Serous Cancer Risk Assessment

Abstract

The proposal was designed to address three issues. First could we identify stem cells from the fallopian tube, including from patients with high grade serous cancer (HGSC). Second, could we link the molecular abnormalities in cancer associated stem cells and validate them in pathologic material, specifically in what we feel are stem cell outgrowths or SCOUTs and third could we identify molecular alterations that would place the oviduct or the patient at risk for HGSC. In essence we wished to drill down to the cell of origin and link it to cancer risk, identifying an assay that could predict the presence of cancer by analyzing lower genital tract fluids or other samples. All of these aims have been addressed and our studies have reinforced the likelihood that novel pathways to ovarian cancer exist, but evidencepoints to more than one mechanism and site of origin.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jun 01, 2017
Accession Number
AD1055806

Entities

People

  • Christopher P Crum

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Cancer
  • Cells
  • Detection
  • Diseases And Disorders
  • Epithelium
  • Health Services
  • Materials
  • Medical Personnel
  • Neoplasms
  • Ovarian Cancer
  • Physicians
  • Risk
  • Risk Analysis
  • Stem Cells
  • Urogenital System

Readers

  • Oncology (Cancer Research).
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.

Technology Areas

  • Biotechnology